These powerful but little-known companies that have been blamed for high drug prices are now coming out of the shadows for a congressional interrogation

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 51%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

The US has a high drug prices problem. These obscure but powerful companies will now face some tough questions on Capitol Hill.

That's more than last year, when the prices of roughly 2,550 drugs were increased. But this time, the price hikes seem to have been more spread out, with drugmakers waiting"until March instead of January, to avoid scrutiny," said Michael Rea, the founder and CEO of Rx Savings Solutions.

It appears that"drug companies were much more conscientious about their tactics to raise prices this year," Rea said. These calculations are based on the"list price" of a drug, which a drug company gets to decide. The backlash about high drug prices has been focused on drugmakers because, at the end of the day, prices are their purview.

But PBMs also get involved in pricing, playing different drug companies against eachother to negotiate, because bigger and bigger discounts force them to hike prices, and so on.As PBMs have been blamed for the US drug price problem, the face of the PBM industry has been changing. PBMs are increasingly now in-house, folded into the larger corporate machinery of health insurers or even pharmacy chains. So that's who you'll see before the Senate Finance committee on Tuesday.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 729. in BE

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

How cutting Obamacare could help drug companies keep prices highPresident Trump has promised to take on big drug companies and drug pricing, but he’s also promised to take out Obamacare. Ali Velshi and Stephanie Ruhle break down how cutting Obamacare could help companies keep prices high. Senator Ron Wyden joins the conversation with his plans to make prescription drugs more affordable. Someone ACTUALLY talking about the issues..FINALLY. Nationalization Prices are high because both D and Rs aren't allowing imports from other countries. We are forced to buy from big pharma because of this.
La source: MSNBC - 🏆 469. / 51 Lire la suite »